Opinion/decision on a Paediatric investigation plan (PIP): Libmeldy,atidarsagene autotemcel, decision type: , therapeutic area: , PIP number: P/0455/2022

Opinion/decision on a Paediatric investigation plan (PIP): Kerendia,Finerenone, decision type: , therapeutic area: , PIP number: P/0434/2022

Opinion/decision on a Paediatric investigation plan (PIP): Tremfya,Guselkumab, decision type: , therapeutic area: , PIP number: P/0435/2022

Opinion/decision on a Paediatric investigation plan (PIP): Livmarli,Maralixibat chloride, decision type: , therapeutic area: , PIP number: P/0436/2022

Opinion/decision on a Paediatric investigation plan (PIP): outer membrane vesicles (OMV) from n.

EMA recommends non-renewal of authorisation of Duchenne muscular dystrophy medicine Translarna

Opinion/decision on a Paediatric investigation plan (PIP): Treprostinil sodium, decision type: , therapeutic area: , PIP number: P/0427/2022

Tenth industry stakeholder platform on research and development support, from 11/07/2023 to 11/07/2023

Human medicines European public assessment report (EPAR): Azacitidine Mylan, azacitidine, Myelodysplastic Syndromes;Leukemia, Myelomonocytic, Chronic;Leukemia, Myeloid, Acute, Date of authorisation: 27/03/2020, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Saxenda, liraglutide, Obesity;Overweight, Date of authorisation: 23/03/2015, Revision: 14, Status: Authorised